Search clinical trials for: Radionuclide venography

Total 255 results

UNICANCER

Terminated

Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer

Breast Cancer

France
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma

United States
Tel-Aviv Sourasky Medical Center
Tel Aviv Medical Center

Completed

Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome

Long QT Syndrome

Israel
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Colorectal Cancer | Metastatic Cancer

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Recruiting

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis

United States, Canada
University of Leeds
Lund University; University of Turku; University Hospital, Bordeaux; University... and other collaborators

Recruiting

Prognostic Imaging Biomarkers for Diabetic Kidney Disease (iBEAt)

Diabetic Kidney Disease

Finland, France, Italy, Sweden, Switzerland, United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian Carcinoma

United States, Korea, Republic of
Melanoma and Skin Cancer Trials Limited

Recruiting

Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM)

Metastatic Merkel Cell Carcinoma

Australia
National Cancer Institute (NCI)

Active, not recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

Lung Cancer

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ovarian Endometrioid Adenocarcinoma | Fallopian Tube Carcinoma | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Ovarian Serous Surface Papillary Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Metastatic Digestive System Neuroendocrine Tumor G1 | Metastatic Carcinoid Tumor | Recurrent Digestive System Neuroendocrine Tumor G1 | Regional Digestive System Neuroendocrine Tumor G1 | Midgut Neuroendocrine Tumor G1 | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine Tumor | Neuroendocrine...

Canada, United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
Children's Cancer and Leukaemia Group

Withdrawn

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

Neuroblastoma
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma

United States
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Stage I Cervical Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Malignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Fallopian Tube Carcinoma | Ovarian Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Ovarian...

United States
Seoul National University Hospital

Completed

Ultrasound-assisted Versus Conventional Landmark-guided Paramedian Spinal Anesthesia in Elderly Patients

Ultrasonography | Anesthesia, Spinal

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm

United States
Centre Oscar Lambret
Institut National de la Santé Et de la Recherche Médicale, France; National... and other collaborators

Active, not recruiting

Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. (SENTIRAD)

Endometrial Carcinoma

France
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
Cairo University
shaimaa Mostafa; Yasmin Zakaria; Ibrahim Fawzy; Mona Aboulghar; Mona Fouad

Recruiting

Comparison of the Diagnostic Accuracy of Hysterosalpingo-lidocaine-foam Sonography Versus Hysterosalpingography in Tubal Patency Assessment to the Gold Standard of Laparoscopy and Dye Testing

Tubal Factor Infertility

Egypt
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Serous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States, Puerto Rico
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Hematopoietic and Lymphoid Cell Neoplasm | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Locally Advanced Uterine Corpus Leiomyosarcoma | Metastatic Uterine Corpus Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Uterine Corpus Leiomyosarcoma

United States, Puerto Rico
National Cancer Institute (NCI)

Suspended

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Refractory Neuroblastoma | Refractory Osteosarcoma

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia

Search clinical trials for: Radionuclide venography

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations